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Abstract
Clusterin was the first described secreted mammalian chaperone and is implicated as being a key player in both intra- and
extracellular proteostasis. Its unique combination of structural features and biological chaperone activity has, however,
previously made it very challenging to express and purify the protein in a correctly processed and chaperone-active form.
While there are multiple reports in the literature describing the use of recombinant clusterin, all of these reports suffer from
one or more of the following shortcomings: details of the methods used to produce the protein are poorly described, the
product is incompletely (if at all) characterised, and purity (if shown) is in many cases inadequate. The current report
provides the first well validated method to economically produce pure chaperone-active recombinant clusterin. The
method was developed after trialling expression in cultured bacterial, yeast, insect and mammalian cells, and involves the
expression of recombinant clusterin from stably transfected HEK293 cells in protein-free medium. The product is expressed
at between 7.5 and 10 mg/ml of culture, and is readily purified by a combination of immunoaffinity, cation exchange and
size exclusion chromatography. The purified product was shown to be glycosylated, correctly proteolytically cleaved into a-
and b-subunits, and have chaperone activity similar to that of human plasma clusterin. This new method creates the
opportunity to use mutagenesis and metabolic labelling approaches in future studies to delineate functionally important
sites within clusterin, and also provides a theoretically unlimited supply of recombinant clusterin which may in the future
find applications in the development of therapeutics.
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Introduction
Clusterin (CLU) was the first described extracellular mamma-
lian chaperone [1] and can interact with a wide variety of
misfolded proteins to stabilise them in a soluble form, until the
bound protein can be re-folded or degraded [1,2,3]. CLU binds
preferentially to intermediate folding states of proteins that are
slowly aggregating, long-lived and precipitation bound [4], and
can inhibit both amorphous and amyloid pathways of aggregation
[5,6,7]. In vivo, in a rat model, complexes formed between CLU
and misfolded client proteins are rapidly cleared by hepatocytes
and degraded within lysosomes; receptor-mediated endocytosis by
scavenger receptors is implicated in the clearance [2]. It has been
proposed that CLU is one of a family of extracellular chaperones
that act to clear extracellular body fluids of toxic aggregating
proteins, and thus plays a pivotal role in extracellular protein
homeostasis (proteostasis) [8]. As a case in point, it was recently
shown that changes in the clusterin gene can pose a very
significant risk factor in Alzheimer’s disease [9,10] and that CLU
reacts with a variety of Ab oligomers, ranging from monomers to
50-mers, to inhibit their aggregation and toxicity [11]. Further-
more, under conditions of endoplasmic reticulum (ER) stress, CLU
can retrotranslocate from the secretory pathway into the cytosol
where it can also contribute to the maintenance of intracellular
proteostasis [12,13]. Thus CLU is currently unique in that it is the
only chaperone known to participate in processes of both intra-
and extra-cellular proteostasis.
Despite this unique position, and considerable interest in CLU
for its roles in proteostasis, many serious protein misfolding
diseases and cancer [8], very little is known about the structure-
function relationships of the molecule. There have been no crystal
structure determinations for the protein, and only limited analyses
by mass spectrometry [14,15] and NMR [4]. What little is known
about the structure comes largely from predictions based on amino
acid sequence analyses [16]. Inferences about the potential
location of CLU binding sites for the low density lipoprotein
receptor-related protein 2 (LRP-2; glycoprotein 330/megalin)
receptor and misfolded proteins have been drawn from fortu-
itously truncated versions of recombinant CLU (rCLU) expressed
in yeast [17] but are yet to be clearly identified. Similarly, other
regions of the protein that may be critical in the chaperone action
are currently unknown.
CLU is translated on cytosolic ribosomes with a 22-mer ER
signal sequence which is cleaved once the protein enters the ER, to
produce a 427 amino acid polypeptide with a predicted mass of
50,062 Da. The protein is subsequently internally proteolytically
cleaved in the Golgi to generate the a- and b-chains which are
joined by 5 disulfide bonds [18]. The protein is also heavily
glycosylated at multiple sites, to give 17–27% carbohydrate by
mass, which results in SDS-PAGE in the protein having an
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apparent mass of 75–80 kDa (the actual mass is approximately
58–63 kDa; [15]). Thus CLU undergoes extensive eukaryote-
specific post-translational modification. This structural complexity,
together with the propensity of CLU to form very stable complexes
with other proteins that misfold during extended cell culture
[14,19], make CLU particularly challenging to generate as a
recombinant product. These challenges have previously impeded
conventional mutagenesis approaches and made other structural
determinations of the molecule difficult.
Clearly bacteria are unable to perform the proteolytic cleavage
of CLU into a- and b-chains, or to glycosylate the protein. It is
known that human plasma CLU maintains chaperone action
when enzymatically deglycosylated [14], however, it is unknown
whether the a-b cleavage is required for chaperone activity.
Therefore, bacterial expression systems (which are fast and
relatively cheap) might in theory be capable of producing
chaperone-active rCLU, although eukaryotic systems offer the
advantage of fuller post-translational modifications.
When we previously expressed rCLU in Sf9 Spodoptera frugiperda
(insect) cells, the product was not proteolytically cleaved into a-
and b-chains, had variable levels of glycosylation and a low yield (F
Dawes, unpublished data). Another group used baculovirus to
express rCLU in H5 Trichoplusia ni (insect) cells, which resulted in
an under-glycosylated, non-secreted product that had not been
post-translationally cleaved into mature a- and b-chains [20],
indicating that these may be common problems when expressing
rCLU in insect cells. We also previously expressed a glycosylated,
disulphide-bonded a-b clusterin dimer in the yeast Pichia pastoris,
however, the product was partially proteolytically degraded [17].
Other groups have expressed rCLU in E. coli [21], yeast [22]
and various mammalian cell lines [23,24,25]. In these studies,
however, rCLU was not well characterised; typically a Western
blot was performed to verify the identity of the product (although
in some cases this was not shown), and in most cases SDS-PAGE
analyses were not shown nor the purity of the sample described.
Methods used to purify rCLU are also poorly described in these
publications, making it hard to reproduce and/or validate the
methods. Furthermore, critically, none of these previous studies
attempted to verify that the product was chaperone-active.
Collectively, the available information raises questions about
whether any previously published study has in fact produced ‘pure’
appropriately post-translationally processed rCLU, let alone a
functionally active product. Therefore, to enable future progress in
understanding the structure-function relationships of this impor-
tant chaperone and its roles in proteostasis and disease, there was
an urgent need to develop a successful method to produce pure,
chaperone-active rCLU; development of a suitable method
involving expression from transfected HEK293 cells cultured in
protein-free medium is described below.
Methods
Ethics
Human blood was obtained as a gift from Wollongong hospital
and ethics approval for this was obtained from the Human Ethics
Committee at the University of Wollongong (HE02/080). All
donors were being treated by routine venepuncture for polycy-
themia or other conditions and gave their consent in writing prior
to blood collection.
SDS-PAGE
The purity and molecular weight of protein samples were
assessed using SDS-PAGE. Samples were prepared in 1X sample
buffer (60 mM Tris pH 6.8, 1% (w/v) SDS, 10% (v/v) glycerol,
0.01% (w/v) bromophenol blue) and heated at 100uC for 5 min
prior to loading on the gel. Samples were loaded onto a 10% (v/v)
SDS-PAGE gel and electrophoresed at 120 V in a HoeferTM SE
250/260 SDS-PAGE apparatus (GE Healthcare, Chalfont St
Giles, UK) and subsequently stained in Coomassie Blue (0.2% (w/
v) Coomassie Blue R250, 40% (v/v) methanol, 10% (v/v) glacial
acetic acid in distilled water (dH2O)) and destained in 40% (v/v)
methanol, 10% (v/v) glacial acetic acid and 50% (v/v) dH2O.
Immunoblotting
For Western blots to detect CLU, samples were electrophoresed
on a 10% SDS-PAGE gel followed by electrophoretic transfer
using a Trans-blot (Bio-Rad, Hercules, CA, USA) apparatus.
Following protein transfer, the nitrocellulose membrane (Pall
Corporation, Pensacola, FL, USA) was blocked overnight at 4uC
in HDC/PBS (1% (w/v) heat denatured casein +0.01% (w/v)
thimerosal in phosphate buffered saline (PBS): 137 mM NaCl,
2.7 mM KCl, 7.9 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4).
After blocking, a 1:1 mixture of undiluted G7 and 41D hybridoma
culture supernatants [26] was added to the membrane and
incubated for 1 h at 37uC with shaking prior to washing. Between
each incubation the membrane was washed with 0.1% (v/v)
Triton X-100 (Tx-100) in PBS three times followed by a rinse with
PBS. The secondary antibody used was either goat-anti-mouse-
HRP or sheep-anti-mouse-HRP (both from Millipore, Billerica,
MA, USA) diluted 1:1,000 in HDC/PBS and incubated as above.
An enhanced chemiluminescence (ECL) kit (Supersignal Western
Pico substrate working solution; Thermo Scientific, Rockford, IL,
USA) and Amersham Hyperfilm ECL (GE Healthcare) were used
for development, as per the manufacturer’s instructions. For
immuno dot blot analyses of HEK293 cell culture supernatants,
aliquots from a binary dilution series of the sample were spotted
onto nitrocellulose membrane. For comparison, known concen-
trations of wild type CLU purified from human plasma (wtCLU;
see below) were also spotted onto the membrane. After air drying,
the membrane was blocked and probed for CLU as described
above.
Expression of Recombinant CLU in Escherichia coli
E. coli was routinely cultured in Luria Bertani (LB) broth (10 g/l
tryptone, 5 g/l yeast extract, 171 mM NaCl in dH2O), or on LB
agar (LB broth supplemented with 15 g/l agar) plates. Electro-
competent E. coli were transformed with a pDEST42 expression
vector (Invitrogen, now Life TechnologiesTM; Carlsbad, CA, USA)
containing human CLU cDNA (Uni-Prot P10090-1) using a Bio-
Rad Gene Pulser at 2.5 KV, 25 mFD and 200 V, and subsequently
cultured in the presence of 100 mg/ml ampicillin. Overnight
starter cultures were used to inoculate 1,000 ml of pre-warmed LB
broth containing 100 mg/ml ampicillin. The culture was grown at
37uC with shaking at 200 rpm until an optical density of 600 nm
(OD600) of 0.8 was reached before inducing expression with
0.3 mM IPTG and shaking at 200 rpm overnight at 24uC. Cells
were pelleted by centrifugation at 5,0006g for 15 min at 4uC.
Purification of Recombinant CLU Expressed in E. coli
All bacterially expressed recombinant CLU (b-rCLU) was found
in inclusion bodies; to extract b-rCLU, the bacterial pellet was
resuspended in 5 ml lysis buffer (300 mM NaCl, 46.6 mM
Na2HPO4, 3.4 mM NaH2PO4, 0.75 mg/ml lysozyme, 10 U/ml
DNase 1, 1 mM PMSF; pH 8.0) per gram of pellet. During
resuspension a CompleteH Protease Inhibitor Cocktail tablet
(Roche Diagnostics Australia; Castle Hill, NSW, Australia) was
added. The suspension then underwent three freeze/thaw cycles
using liquid nitrogen and a 37uC water bath respectively. The
Producing Chaperone-Active Recombinant Clusterin
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solution was pelleted at 10,0006g for 30 min and the supernatant
discarded. The pellet was resuspended in 25 ml of wash buffer
(300 mM NaCl, 46.6 mM Na2HPO4, 3.4 mM NaH2PO4, 0.5%
(v/v) Tx-100; pH 8.0) and centrifuged at 25,0006g for 30 min,
this step was repeated four times to wash away any proteins that
may have non-specifically adsorbed to the hydrophobic inclusion
bodies. The pellet was next resuspended in 5 ml of solubilisation
buffer (300 mM NaCl, 46.6 mM Na2HPO4, 3.4 mM NaH2PO4,
8 M urea, 10 mM dithiothreitol (DTT), pH 8.0), gently shaken
overnight at 4uC to dissolve, and then centrifuged for 30 min at
25,0006g to remove any remaining insoluble components.
Solubilised inclusion bodies were fractionated on a SuperoseTM
6 10/300 column (GE Healthcare) in solubilisation buffer
(containing 5 mM DTT); fractions identified by SDS-PAGE as
containing b-rCLU (apparent mass of ,50 kDa), with minimal
high molecular weight (HMW) contaminants, were combined for
further use.
A variety of attempts were undertaken to produce a soluble
form of b-rCLU in the absence of reducing agents; in most cases
the removal of urea and DTT from the solution resulted in bulk
protein precipitation (Figure S1). Briefly, these methods included:
a) direct dilution of b-rCLU dropwise into a refolding buffer
(50 mM NaH2PO4, 300 mM NaCl, 1 mM DTT, 10% (v/v)
glycerol, 0.1% (w/v) Az, pH 8), which has previously been used to
refold rCLU fragments [19]; b) direct dialysis of b-rCLU in
solubilisation buffer against PBS, and c) step-wise dialysis against
decreasing concentrations of urea, using 1 M increments from
6 M to 1 M urea (i.e. 5 changes), followed by dialysis against
0.5 M and then 0.25 M urea in PBS before dialysis against 3
changes of PBS/Az (PBS containing 0.1% (w/v) sodium azide).
Only this last method produced soluble b-rCLU, however this
product rapidly and progressively formed HMW aggregates,
suggesting that it was not folded correctly. Therefore reduction
and alkylation was also undertaken to determine if this could
prevent the progressive formation of these HMW species. Briefly,
strong reducing conditions (50 mM DTT for 18 h) were found to
be necessary to dissociate the HMW aggregates formed after the
removal of urea and DTT (as determined by size exclusion
chromatography (SEC; data not shown)) followed by cysteine
capping or alkylation of free thiol groups. After reduction, the
sample was passed over a PD10 column (GE Healthcare)
equilibrated with PBS +3 mM EDTA to remove DTT, and
fractionated into the wells of a quartz 96 well plate. The wells with
the highest absorbance at 280 nm (A280) were pooled and a)
capped with a 100X molar excess of L-cysteine, or b) alkylated
with 50 mM of either iodoacetic acid (IAA), iodoacetamide (IAM),
or N-ethylmaleimide (NEM). All reactions were carried out
overnight at 37uC with shaking.
Expression of Recombinant CLU Secreted by HEK293
Cells
HEK293 cells (ATCC, Manassas, VA, USA) were stably
transfected with the vector pRcCMV containing human CLU
cDNA (Uni-Prot 10090-1) using lipofectamine (Life Technolo-
giesTM) following the manufacturer’s protocol. After transfection
the cells were grown in DMEM:F-12 containing 10% (v/v) foetal
calf serum (FCS) and 600 mM geneticin. To initially confirm
secretion of mammalian cell-expressed recombinant CLU (m-
rCLU), supernatant was collected from the HEK293 transfectants
(this contained 7.5–10 mg/ml of m-rCLU, estimated by immuno
dot blot; data not shown). For large-scale expression, 175 cm2
flasks were seeded to 50% confluency with cells suspended in
35 ml DMEM:F-12 medium supplemented with 5% (v/v) FCS
and incubated for 16–24 h to allow cells to adhere (cells typically
reached 60–80% confluence during this time). The medium
containing FCS was subsequently removed, the cell monolayer
gently rinsed twice with DMEM:F-12 to remove any remaining
traces of FCS, and 35–50 ml of unsupplemented DMEM:F-12
added to the flask. Cells were cultured for a further 7–10 days
without changing the culture medium, after which the supernatant
was centrifuged at 3006g for 5 min to pellet dead cells and debris.
The content of m-rCLU in the clarified cell culture supernatant
was tested by both immunoblot and immuno dot blot procedures.
Purification of m-rCLU and wtCLU
Transfected HEK293 culture supernatant was supplemented
with CompleteH protease inhibitor and filtered through a 0.45 mm
cellulose nitrate filter (Sartorius Stedim Biotech, Goettingen,
Germany). Human blood containing 10 mM sodium citrate was
kindly donated by Wollongong hospital (Wollongong hospital
pathology unit, NSW, Australia); plasma was prepared by
centrifuging the blood at 1,3006g for 30 min at 4uC. CompleteH
protease inhibitor was added and the plasma then filtered through
(i) a GFC glass fibre filter (MicroAnalytic Products Inc., Mountain
Lakes, NJ, USA) to remove any large debris and clots that may
have formed, and then (ii) a 0.45 mm cellulose nitrate filter. A 5 ml
G7 anti-CLU monoclonal antibody column [16] was connected to
an Econo pump system (Bio-Rad) and equilibrated in filtered
PBS/Az. The supernatant or plasma was then pumped over the
column (at 0.5 ml/min or less) to allow CLU to bind, followed by
washing with (i) ,50 ml PBS/Az, then (ii) ,50 ml of 0.5% (v/v)
Tx-100 in PBS (to remove any bound lipids), before re-
equilibrating in PBS/Az. Next, 200 mM sodium acetate, 0.5 M
NaCl, pH 5 was passed over the column to remove non-
specifically bound material. Finally, specifically bound material
was eluted using 2 M GdHCl in PBS and the column immediately
re-equilibrated with PBS/Az for storage at 4uC. Fractions
containing the GdHCl eluate were combined and dialysed against
two changes of 20 mM MES, pH 6.0. A 1 ml HiTrapTM SP XL
cation exchange column (GE Healthcare) was equilibrated in
20 mM MES, pH 6.0, the dialysed fraction loaded and the flow-
through (containing CLU) collected. The bound ‘contaminating’
proteins, typically .250 kDa in size were eluted from the cation
exchange column with 20 mM MES, pH 6.0, containing 1 M
NaCl. An additional ‘clean up’ step of SEC on a SuperoseTM 6
10/300 column, as described below, was undertaken to remove
remaining HMW contaminating proteins.
Circular Dichroism Spectroscopy
A Jasco Model J-810 (Jasco, Easton, MD, USA) spectropolar-
imeter linked to a CDF-426S/L Peltier system (Jasco) was used to
acquire circular dichroism (CD) data. Far-UV (180–250 nm) CD
studies were undertaken to compare the secondary structure of
proteins. Samples were analysed using a 1 mm CD cell, acquiring
spectra at a sensitivity of 100 millidegrees and a bandwidth of
1 nm. The scanning mode was continuous at 50 nm/min and 6
data sets were accumulated before the average was displayed.
SEC Analysis
Proteins were loaded onto a SuperoseTM 6 10/300 column
equilibrated in PBS/Az using an ÄKTA FPLC system at 0.3 ml/
min and the A280 of the eluate monitored continuously. Mass
standards were from a commercial HMW calibration kit (GE
Healthcare). All buffers and samples were filtered (0.45 mm) before
use.
Producing Chaperone-Active Recombinant Clusterin
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e86989
Chaperone Function Assays
Client proteins were induced to amorphously precipitate using
either heat or reductive stress; in all cases, assays were performed
in flat bottom 384 well plates (Greiner Bio-One; Kremsmunster,
Austria) with a final volume of 50–100 ml/well. Protein aggrega-
tion was continuously measured as turbidity (A360) using a
FLUOstar OPTIMA plate reader (BMG Labtech; Ortenberg,
Germany). The putative chaperone proteins (and control proteins)
being tested were added at different concentrations to determine
whether they could inhibit client protein precipitation. As the
precise molecular mass of rCLU was not known (although it
should be similar to wtCLU), mass ratios were used to compare the
chaperone efficacy of rCLU versus wild type CLU purified from
human plasma (wtCLU; see below). The chaperone activity of b-
rCLU was tested against bovine serum albumin (BSA) and
glutathione-S-transferase (GST), using the following conditions:
BSA (1.5 mg/ml) was reduced by incubation (without shaking) for
16 h at 37uC in PBS/Az containing 20 mM DTT, and GST
(500 mg/ml) was heated for 3–4 h at 60uC in PBS/Az. The
chaperone activity of m-rCLU was tested using 3 client proteins:
BSA (as described above), citrate synthase (CS) and creatine
phosphokinase (CPK). CS and CPK were heated for 3–4 h at
43uC under the following conditions (with A360 readings taken
every 1 min); CS (200 mg/ml) in TE buffer (50 mM Tris, 2 mM
EDTA, pH 8) with 3 s double orbital shaking (1 mm shaking
width, 600 rpm) after each read; CPK (1.12 mg/ml) in PBS/Az
with 10 s double orbital shaking (1 mm shaking width, 600 rpm)
after each read. BSA and ovalbumin (OVA) were used as non-
chaperone control proteins.
Results
Characterisation of rCLU Expressed in E. coli
Extraction of inclusion bodies in solubilisation buffer containing
8 M urea yielded 100–120 mg protein/L bacterial culture, in
which b-rCLU was by far the dominant protein present (data not
shown). To remove minor impurities, solubilised inclusion bodies
were subjected to SEC in a buffer containing 8 M urea and 5 mM
DTT. Subsequent SDS-PAGE analysis of the purified b-rCLU
showed a major species migrating at ,45 kDa (Figure 1A),
corresponding to the expected size of uncleaved, unglycosylated
CLU, similar to the apparent mass of deglycosylated wtCLU in
SDS-PAGE [14,19]. However, once urea and DTT were removed
by step-wise dialysis, HMW aggregates began to form (Figure 1B),
presumably due to the progressive generation of inappropriate
inter-molecular disulphide bonds between b-rCLU molecules. A
minor band at ,35 kDa was also detected by SDS-PAGE and
Western blot analysis using anti-CLU antibodies (data not shown),
which may represent a cleavage product of b-rCLU. Prior to
dialysis of the solubilised inclusion bodies, when analysed by SEC
in the presence of urea and DTT, b-rCLU migrated as a broad
asymmetric peak with a maximum absorption at an elution
volume of approximately 14 ml (,450 kDa) (Figure 2A). After
step-wise dialysis into PBS, although b-rCLU remained soluble,
almost all the protein had formed HMW aggregates that ran at the
size exclusion limit of the column (46107 Da); a minor peak at
,18 ml (,67 kDa) probably represents minor proteolytic frag-
ment(s) (Figure 2A). In contrast, as expected, wtCLU migrated as a
mixture of oligomeric species [1,14,27], with multiple peaks
eluting between 7.9 ml and 17 ml (between 46107 Da and
67 kDa) (Figure 2A).
It was found to be possible to reverse the aggregation of b-rCLU
induced by removal of urea and DTT by strong reduction
followed by cysteine capping or alkylation of free –SH groups.
Although this was successful in substantively decreasing the size of
species in solution (data not shown), circular dichroism (CD)
spectroscopy indicated that all of these treatments induced
considerable changes in secondary structure content (Figure 2B).
The far UV CD spectra of b-rCLU that had been reduced and
then alkylated or cysteine capped was significantly different to that
of the starting material, which although inappropriately aggregat-
ed had a near-identical CD spectrum to wtCLU (Figure 2B).
The chaperone activity of HMW b-rCLU was tested against
two client proteins induced to aggregate using either heat (GST) or
reductive stress (BSA) (Figure 3). Under all conditions tested, all
forms of b-rCLU (including reduced and alkylated/capped forms;
data not shown) lacked any detectable chaperone activity. In
contrast, wtCLU dose dependently inhibited protein precipitation.
As the bacterial expression system appeared incapable of
producing a chaperone-active form of rCLU, a mammalian
expression system was next investigated.
Characterisation of rCLU Secreted by Transfected HEK293
Cells
Compared to when transfected HEK293 cells were grown in
medium containing FCS, the removal of FCS from the culture
medium during expression significantly reduced the levels of
HMW species in the purified sample (detected by non-reducing
SDS-PAGE; Figure 4A, lane 2). Under reducing conditions, this
HMW material dissociated into multiple bands of lower molecular
weight, consistent with the reduction-induced dissociation of
clusterin-client protein complexes (Figure 4A, lane 3). Similar
Figure 1. Images of Coomassie blue stained SDS-PAGE gels
analysing b-rCLU. (A) Lane 1: Molecular weight markers with size
indicated in kDa. Lane 2: Sample of b-rCLU after SEC purification in
solubilisation buffer containing 8 M urea and 5 mM DTT. (B) Lane 1:
Molecular weight markers with size indicated in kDa. Lane 2: Sample of
b-rCLU after step-wise dialysis into PBS/Az.
doi:10.1371/journal.pone.0086989.g001
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analyses detected low levels of HMWmaterial in m-rCLU purified
from protein-free culture medium, but this was at comparably low
levels to those detected in wtCLU purified from human plasma
(Figure 4B). These HMW bands may represent SDS-resistant
CLU oligomers or complexes formed between CLU and other
proteins (as they react with anti-CLU antibodies in immunoblots;
data not shown). Non-reducing SDS-PAGE analysis of m-rCLU
detected a major band at,75 kDa and a minor band at,53 kDa
(which may represent incompletely glycosylated CLU); wtCLU
was detected as a major band at ,85 kDa (Figure 4B). Reducing
SDS-PAGE detected a band at ,30 kDa for m-rCLU and at
,35 kDa for wtCLU (Figure 4C); in both cases these bands
correspond to the co-migrating a- and b-chains of CLU,
indicating that m-rCLU was correctly post-translationally cleaved.
The differences in mass between m-rCLU and wtCLU are most
likely due to lower levels of glycosylation of m-rCLU by HEK293
cells. In both reduced samples minor bands between 50 and
85 kDa were present (Figure 4C), which may represent incom-
pletely reduced forms and/or minor uncleaved species, which
have been seen elsewhere [28].
SEC analysis of m-rCLU showed that it migrated as a broad
peak between 7 and 15 ml (i.e. ranging from .1000 kDa down to
,100 kDa), with a maximum absorbance at 11.7 ml (,600 kDa)
(Figure 5A). In contrast wtCLU showed a bias towards smaller
species, with several peaks between 10 and 16 ml (i.e. ranging
from ,800 kDa down to ,100 kDa) and a maximum absorbance
at 13.6 ml (,400 kDa). Other minor peaks were also detected for
wtCLU at 15.5 ml and for m-rCLU at 15.9 ml (,200 kDa)
(Figure 5A). Thus m-rCLU and wtCLU span the same very broad
size range of species in solution but m-rCLU contains more larger
species than wtCLU. The far UV CD spectra of m-rCLU and
wtCLU are very similar (Figure 5B), indicating that they are also
similar in secondary structure content.
The chaperone activity of m-rCLU was tested using a range of 3
client proteins. Like wtCLU, m-rCLU dose-dependently inhibited
the reduction-induced precipitation of BSA; a concentration of
0.2 mg/ml (corresponding to a mass ratio of chaperone to client of
Figure 2. SEC and circular dichroism (CD) analyses of b-rCLU and wtCLU. (A) A280 traces of SEC separations performed using a Superose
TM6
10/300 SEC column. The positions and masses (in kDa) of molecular weight markers are indicated by labelled arrows; the exclusion limit of the
column (Vo) $4610
7 Da. For visual clarity the traces for b-rCLU (after step-wise dialysis into PBS) and wtCLU (in PBS) are deliberately vertically offset
from that of b-rCLU fractionated in solubilisation buffer containing 8 M urea and 5 mM DTT. (B) CD plots represent mean molar ellipticity of 6
acquisitions. Similar results were obtained with IAA- and NEM-alkylated b-rCLU (data not shown).
doi:10.1371/journal.pone.0086989.g002
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1:7.5) fully inhibited precipitation of BSA (Figure 6A). Even at
0.75 mg/ml, the non-chaperone control protein OVA had no
significant effect on the precipitation of BSA. Under these
conditions, m-rCLU showed comparable chaperone activity to
wtCLU at all concentrations tested (Figure 6A). In a second series
of chaperone assays, like wtCLU, m-rCLU dose dependently
inhibited heat-induced CS precipitation, though complete inhibi-
tion was not seen even at a 1:1 mass ratio of m-rCLU to CS.
Although m-rCLU was able to inhibit aggregation of CS, it was
less effective than wtCLU against this client protein (Figure 6B). At
0.2 mg/ml wtCLU inhibited end-point precipitation of CS by
93% compared to 72% by m-rCLU; corresponding levels of
inhibition for wtCLU and m-rCLU at 0.1 mg/ml and 0.05 mg/
ml were 83% versus 29% and 46% versus 15%, respectively. A
third series of chaperone assays were performed using CPK as the
client protein (Figure 6C). Like wtCLU, m-rCLU dose depen-
dently inhibited CPK precipitation. At a mass ratio of m-rCLU to
CPK of 1:5.6, m-rCLU fully inhibited the precipitation of CPK
and was able to do this at a chaperone:client mass ratio
approximately half that required for wtCLU (1:5.6 versus 1:2.24,
respectively).
Discussion and Conclusions
Bacterial expression systems typically produce high levels of
recombinant products and are frequently used for the expression
of proteins, however, they do not perform post-translational
modifications. As the chaperone activity of CLU is not substan-
tively affected by deglycosylation, we therefore investigated the
potential to express rCLU in bacteria. CLU expressed in E. coli
was found contained within the insoluble inclusion body fraction.
To solubilise the b-rCLU contained in the inclusion bodies, 8 M
urea and 10 mM DTT were required. Once solubilised, quick
removal of the urea and DTT resulted in gross precipitation of b-
rCLU from solution. Slower removal of these agents by step-wise
dialysis maintained b-rCLU in solution but primarily as inappro-
priately disulphide-bonded HMW aggregates. It was possible to
dissociate the HMW aggregates so formed by strong reduction,
and to prevent their subsequent re-aggregation by alkylation (or
cysteine capping) of reduced thiol groups on b-rCLU, but this had
the consequence of inducing substantive differences in secondary
structure content relative to wtCLU. Critically, all forms of b-
rCLU produced that were soluble in physiological buffer (i.e. the
Figure 3. Chaperone assays for b-rCLU and wtCLU using 2 client proteins. (A) GST was heated at 60uC; BSA (negative control protein),
wtCLU (positive control) and b-rCLU were tested at the concentrations indicated. The A360 is plotted at 6 min intervals (mean6 standard deviation; n
= 3). (B) BSA (1.5 mg/ml) was reduced with 20 mM DTT; wtCLU (positive control) and b-rCLU were tested at the concentrations indicated. The A360 is
plotted at 12 min intervals (mean 6 K range; n = 2).
doi:10.1371/journal.pone.0086989.g003
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absence of urea), including HMW b-rCLU and forms that had
been strongly reduced and then alkylated or cysteine capped,
lacked chaperone activity. Therefore another approach to produce
functional rCLU was needed.
Previous work has shown that obtaining pure rCLU from
mammalian cell expression systems is difficult [19]. Mammalian
culture media proteins are subjected to sustained elevated
temperature (37uC) and shear stress if the cultures are agitated.
These conditions result in the progressive misfolding of some of the
media proteins. The well-characterised chaperone action of CLU
means that it will bind to these misfolded proteins to form soluble
HMW complexes [1,4,8]. In the mammalian body these
complexes are rapidly cleared [2], but in most cell culture systems
these clearance mechanisms are not available, meaning that the
HMW complexes remain in the medium and co-purify with
rCLU. Previously, separating the HMW complexes from non-
complexed rCLU proved difficult, and the yield was low [19].
We report here an optimised mammalian expression system
using stably transfected HEK293 cells. The optimised method
involved growing stably transfected HEK293 cells expressing m-
rCLU in culture medium containing 10% (v/v) FCS, in which
they grew satisfactorily and remained viable. To express m-rCLU,
the cells were first passaged in DMEM:F-12 medium containing
5% (v/v) FCS, allowed to adhere to the culture surface for 16–
24 h, and then cultured in FCS-free DMEM:F-12 medium for a
subsequent 7–10 days before harvesting the culture supernatant.
Removal of all protein from the end-stage culture medium was
found to be essential to minimise the formation of stable high
molecular weight chaperone-client complexes between clusterin
and media proteins. Under these conditions 7.5–10 mg/ml m-
rCLU was recovered from the culture supernatant (estimated by a
semi quantitative immuno dot blot; data not shown). After 3-step
purification (using G7 anti-CLU affinity chromatography, cation
exchange chromatography and SEC) and concentration, 1 litre of
tissue culture supernatant yielded ,4.5 mg of pure, chaperone
active m-rCLU. It may be possible to enhance this yield by simply
increasing the density of HEK293 cells incubated in the protein-
free medium (e.g. by using a suspension culture), but this remains
to be confirmed.
Non-reducing SDS-PAGE analysis showed that m-rCLU
migrated as a lower mass species than wtCLU (,75 kDa versus
,85 kDa, respectively). The apparent molecular weight of the a-
and b-chains under reducing conditions was also smaller for m-
rCLU (,30 kDa) than wtCLU (,35 kDa). This demonstrates
that, like wtCLU, HEK293 expressed m-rCLU is a disulphide-
bonded heterodimer comprised of a- and b-chains, and suggests
that HEK293 cells glycosylate m-rCLU to a lesser extent than
wtCLU. In fact, wtCLU purified from human plasma has been
secreted by a variety of tissues, and thus represents a mixture of
species with different types and levels of glycosylation [15] (but is
probably dominated by clusterin secreted by the liver). HEK293 is
an embryonic kidney cell line, and so will endow clusterin with its
own unique level of glycosylation. Different levels of clusterin
glycosylation is expected from differing cell types, as we have
previously seen for clusterin expressed in yeast and insect cells
([17]; F Dawes, unpublished data).
CLU typically exists in physiological solution as a mixture of
oligomers [1]; this characteristic of polydispersity is shared by a
Figure 4. Images of Coomassie blue stained SDS-PAGE gels analysing m-rCLU secreted into FCS-supplemented versus serum-free
media. (A) m-rCLU purified from culture medium containing 10% FCS, Lane 1: Molecular weight markers with size indicated in kDa; Lane 2: non-
reducing; Lane 3: reducing conditions. (B) Non-reducing and (C) reducing SDS-PAGE analyses of m-rCLU purified from serum-free media and wtCLU.
In (B) and (C), Lane 1: Molecular weight markers with size indicated in kDa; Lane 2: Purified m-rCLU; Lane 3: Purified wtCLU.
doi:10.1371/journal.pone.0086989.g004
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number of chaperones including the sHSPs [29]. As has been
previously shown by Stewart et al. (2007) and in this study, when
analysed by SEC a small fraction of wtCLU ran at the size
exclusion limit of the column ($46107 Da), and a major peak was
detected at ,400 kDa. In this study, compared to wtCLU, the
forms of m-rCLU in solution were biased towards higher
molecular weight species. Deglycosylated CLU has previously
been shown to migrate in SEC as a broad peak with a maximum
at ,900 kDa [14]. Thus, the lower levels of glycosylation of m-
rCLU, relative to wtCLU, may have the effect of increasing the
mean size of oligomers in solution, but this remains to be
definitively established. In the human body wtCLU is produced by
many different types of tissues/cells and typically blood from more
than one donor is pooled and used to purify wtCLU, leading to a
sample with heterogeneous glycosylation levels.
CD analysis showed that m-rCLU had similar secondary
structure content to wtCLU, as expected. It was previously shown
that deglycosylated CLU has a similar secondary structure content
to wtCLU [14]. HEK293 expressed m-rCLU was chaperone
active against all three client proteins tested. Depending on the
individual client protein, m-rCLU showed either the same,
increased or decreased ability to inhibit precipitation compared
to wtCLU. These client protein-dependent differences in relative
chaperone activity may relate to differences in glycosylation and/
or solution size between m-rCLU and wtCLU, although further
work would be required to confirm this.
HEK293 cell expressed m-rCLU is cleaved into a- and b-
chains, glycosylated, has a similar secondary structure content to
wtCLU, and is chaperone-active. Therefore, this report provides
the first description of a viable method to produce structurally and
functionally validated rCLU that can in future be used to: (i)
express and characterise CLU mutants, to identify residues
important in structure and function, (ii) metabolically label CLU
for structural studies (e.g. NMR), and (iii) produce large quantities
of rCLU for use as a therapeutic agent to treat a wide range of
protein deposition diseases, or other conditions. It is thought that a
primary physiological role for CLU is as an extracellular
chaperone which stabilises misfolded extracellular proteins and
facilitates their clearance from the body. Thus the development of
a robust source of correctly processed, functionally active rCLU
opens the door to increased understanding of how CLU performs
its physiological roles and potentially gives us the ability to develop
Figure 5. SuperoseTM6 10/300 SEC separations and circular dichroism spectroscopy analysis of m-rCLU and wtCLU. (A) The
SuperoseTM6 10/300 column and samples were in PBS/Az prior to loading. The positions and masses (in kDa) of molecular weight markers are
indicated by labelled arrows; the exclusion limit (Vo) $4610
7 Da. The traces are deliberately vertically offset to more clearly display the results. (B)
Plots represent mean molar ellipticity of 6 acquisitions.
doi:10.1371/journal.pone.0086989.g005
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this new knowledge towards an outcome that will enhance human
health.
Supporting Information
Figure S1 Diagram depicting methods trialled to pro-
duce rCLU in (i) E. coli and (ii) HEK293 cells. (i) Three
methods were tested in an attempt to produce soluble b-rCLU (in
PBS) after extraction from inclusion bodies; a) direct dilution, b)
direct dialysis, and c) step-wise dialysis. Red crosses indicate where
b-rCLU precipitated from solution. Further tests (indicated) were
undertaken with soluble b-rCLU obtained following step-wise
dialysis, the results indicating that the product was misfolded and
lacked chaperone activity. (ii) A mammalian expression system,
using HEK293 cells, was tested using both culture medium
containing foetal calf serum (FCS) and protein free culture
medium. Expression of m-rCLU using protein free culture
medium enabled the production of pure, chaperone-active protein
that was correctly folded and post-translationally processed.
(TIF)
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Figure 6. Chaperone assays of m-rCLU and wtCLU using 3 client proteins. (A) BSA (1.5 mg/ml) was induced to precipitate using 20 mM DTT.
The A360 at 30 min intervals is plotted (mean 6 standard deviation; n = 3). (B) CS (200 mg/ml) and (C) CPK (1.12 mg/ml) were heated at 43uC to
induce precipitation; the A360 (mean 6 standard deviation; n = 3) is plotted at intervals of 5 min (CS) or 10 min (CPK). In all cases, m-rCLU and wtCLU
were tested at a range of concentrations and representative plots shown, and OVA was used as a negative control (at the highest concentration of
CLU tested or greater).
doi:10.1371/journal.pone.0086989.g006
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